Healthcare / Diagnostics & ResearchTaipei Exchange
$16.60
-0.45 (-2.64%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-6.8M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$387M
P/E
276.7x
↑EV/EBITDA
11.9x
↓ROE
0.5%
↑Gross Margin
41.5%
↓Debt/Equity
0.80
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.3%
FCF CAGR
—
FCF margin
-1.8%
FCF / Net income
-5.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $375.9M · net income $1.3M · FCF $-6.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $375.9M | $375.9M | $322.5M | $280.5M | $321.9M |
| Net Income | $1.3M | $1.3M | $1.1M | $-2.6M | $9.6M |
| EBITDA | $32.5M | $32.5M | $33.0M | $26.8M | $32.9M |
| EPS | — | — | 0.05 | -0.11 | 0.41 |
| Gross Margin | 41.5% | 41.5% | 42.1% | 42.7% | 44.1% |
| Operating Margin | 0.0% | 0.0% | -0.2% | -1.7% | 4.9% |
| Net Margin | 0.4% | 0.4% | 0.3% | -0.9% | 3.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.80 | 0.80 | 0.45 | 0.53 | 0.17 |
| Current Ratio | 1.96 | 1.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.8M | $-6.8M | $51.3M | $-28.1M | $24.6M |
| Returns | |||||
| ROE | 0.5% | 0.5% | 0.4% | -0.9% | 3.1% |
| Valuation | |||||
| P/E | 276.67 | 276.67 | 465.00 | — | 52.32 |
| EV/EBITDA | 11.94 | 11.94 | 15.09 | 18.19 | 11.95 |
| P/B | 1.38 | 1.38 | 1.88 | 1.79 | 1.65 |
| Growth & Yield | |||||
| Revenue Growth | 16.6% | 16.6% | 15.0% | -12.8% | — |
| EPS Growth | — | — | 145.5% | -126.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.05 → n/d
Residual
-23.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.